NCT00441493CompletedNot Applicable
A Dose Finding Study of Fluvastatin for in Vivo Demonstration of Inhibiting Hepatitis C Replication in Patients Infected With Chronic Hepatitis C With Special Attention to the African-American Population.
Bader, Ted, M.D.2 sites in 1 country32 target enrollmentStarted: September 1, 2006Last updated:
Conditions
Drugs
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 32
- Locations
- 2
- Primary Endpoint
- Viral Load Reduction, Liver test changes
Study Overview
Brief Summary
This is a dose finding and efficacy trial for fluvastatin versus hepatitis C.
Detailed Description
Four different oral doses of fluvastatin will be used for 14 days and the viral load of hepatitis C will be measured weekly. This has been extended to different doses for 9-12 weeks.
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 75 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •HCV RNA positive
Exclusion Criteria
- •Testing positive for alcohol or marijuana
Outcomes
Primary Outcomes
Viral Load Reduction, Liver test changes
Secondary Outcomes
No secondary outcomes reported
Investigators
Study Sites (2)
Loading locations...
Similar Trials
Completed
Phase 2
Fluvastatin, Rosuvastatin Added to Pegylated Interferon and RibavirinChronic Hepatitis CNCT00487318Bader, Ted, M.D.40
Completed
Phase 4
Fluvastatin in Adults With Dislipidemia With History of Muscle ProblemsDyslipidemiaNCT00125125Novartis218
Withdrawn
Phase 2
A Pilot Trial to Determine the Safety and Efficacy of Fluvastatin in Previous Partial Responders to Pegylated Interferon and Ribivirin in Patients With Genotype 1 Hepatitis CHepatitis C VirusHepatitis CNCT00814606University of Chicago
Completed
Phase 2
Dose-ranging Efficacy and Pharmacokinetics Study of Intravenous Atorvastatin in Hypercholesterolemic PatientsDyslipidemiasHypercholesterolemiaNCT03611010Cumberland Pharmaceuticals40
Withdrawn
Not Applicable
Rosuvastatin for Hepatitis CHepatitis CNCT00371579UMC Utrecht